TD Securities raised its price target on Cannara Biotech (LOVE.TO) to C$4 from C$3.25 on Thursday.
Analysts including Derek J. Lessard maintained a Buy rating on shares of the Canadian cannabis company.
"The company continues to scale profitably, gain share with its high-velocity brands, and broaden its geographic mix; all while adding international upside without overextending," the analyst said.
(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)